|1.||Suzuki, Naomi: 1 article (04/2010)|
|2.||Shibutani, Shinya: 1 article (04/2010)|
|3.||Sayama, Kazutoshi: 1 article (04/2010)|
|4.||Okamoto, Kanako: 1 article (04/2010)|
|5.||Kim, Hyo Jeong: 1 article (04/2010)|
|6.||Laxmi, Y R Santosh: 1 article (04/2010)|
|7.||Okamoto, Yoshinori: 1 article (04/2010)|
|8.||Liu, Xiaoping: 1 article (04/2010)|
|9.||Wallwiener, D: 1 article (09/2003)|
|10.||Seeger, H: 1 article (09/2003)|
|1.||Breast Neoplasms (Breast Cancer)
09/01/2003 - "equilin (Eq) and 17alpha-dihydroequilin (Dheq) on the proliferation of human breast cancer cells. "
02/01/1999 - "Finally, preliminary studies conducted with the human breast tumor cell line MCF-7 demonstrated that the cytotoxic effects of the catechol estrogens from estrone, equilin, and 2-hydroxyequilenin were similar, whereas 4-hydroxyequilenin was a much more potent cytotoxin ( approximately 30-fold). "
04/01/2010 - "For 2.5mg equilin, palpable tumors were observed in 8.3% of the rats after 8 weeks' treatment; the frequency was lower than that (42.9%) observed with 2.5mg E(2). "
04/01/2010 - "ACI rats given 10mg equilin developed palpable mammary tumors at 13 weeks of treatment, and 37.5% of the rats developed mammary tumors within 15 weeks. "
04/01/2010 - "A pellet containing equilin was inserted under the skin of female ACI rats and the development of mammary tumors was monitored. "
04/01/2010 - "Evidently, equilin is a mammary carcinogen, and this potential may be associated with development of breast and reproductive cancers in women receiving hormone replacement therapy."
11/01/1983 - "When equilin and d-equilenin, components of therapeutic conjugated estrogens, were tested, only equilin had a 76% incidence of renal tumor foci (5.5 +/- 0.9). "
|3.||Endometrial Neoplasms (Endometrial Cancer)
|5.||Conjugated (USP) Estrogens (Premarin)
|1.||Hormone Replacement Therapy (Therapy, Hormone Replacement)